Articles tagged ”product launch”

Launching New Anti-FabRICATOR Formats!

May 7, 2021 | New Product, News |

We are happy to announce two new affinity purified antibody formats for detecting the FabRICATOR enzyme!
 
The Anti-FabRICATOR Affinity Purified is an affinity purified goat polyclonal antibody and
the Anti-FabRICATOR Affinity Purified Biotin Conjugated is an affinity purified and biotin-conjugated goat polyclonal antibody.
 
Read more »

NEW SmartEnzymes – Launching FucosEXO!

Genovis launches FucosEXO, an α-fucosidase mix for efficient removal of α1-2, α1-3 and α1-4 linked Fucose on native N- and O-glycosylated proteins. 

 

Analysis of glycoproteins modified with complex glycan structures can be challenging and requires efficient and specific enzymatic tools. FucosEXO is a mix of α-fucosidases for efficient hydrolysis of α1-2, α1-3 and α1-4 linked fucose residues on N- and O-glycoproteins or oligosaccharides, without the need for co-factors or additives.

 

             

 

We have tested FucosEXO on a number of glycoengineered TNFR proteins carrying up to 11 O-glycans decorated with fucose in different linkages, comparing the activity to other commercially available fucosidases. FucosEXO is able to defucosylate the heavily glycosylated TNFR proteins within 1 hour, while treatment with other fucosidases only led to partial removal of fucose or no removal at all.

 

Learn more about FucosEXO for defucosylation of native glycoproteins.

 


 

 

 

FucosEXO enzyme – Lyophilized enzyme for removal of α1-2, α1-3 and α1-4 linked fucose from 2 mg glycoprotein.

 

Immobilized FucosEXO – Immobilized enzyme for removal of α1-2, α1-3 and α1-4 linked fucose from 0.5 mg glycoprotein.

 

 

 

Launching NEW GlyCLICK® ADC kits!

December 10, 2020 | Applications, News, Products |

Genovis launches new GlyCLICK kits for site-specific generation of custom ADCs carrying unique 2-step cleavable linker-payloads from Glykos Finland. 

 

Antibody-drug conjugates (ADCs) comprise a new generation of antibody-based biologics that carry drug payloads directly into target cells, allowing for a broadened therapeutic window. The drawbacks of conventional antibody conjugation strategies are rapidly being surpassed by site-specific methods, where conjugation at the Fc-glycan sites using GlyCLICK has proven to be an attractive option for labeling of native antibodies without genetic engineering.

 

The GlyCLICK conjugation technology results in site-specific incorporation of 2.0 drugs per antibody, for this reason the GlyCLICK ADC kits offer conjugation with highly potent payloads functionalized with DBCO to enable click-chemistry to azide activated antibodies. GlyCLICK ADC kits can be used to combine native IgG with a two-step cleavable linker carrying either MMAE or PNU for the desired cytotoxic effect on targeted cells (Fig. 1).

 

Learn more about the GlyCLICK technology for ADC development.

 


 

 

 

GlyCLICK ADC kit MMAE – Site-specific ADC generation with cleavable linker-payloads carrying MMAE.

 

GlyCLICK ADC kit PNU – Site-specific ADC generation with cleavable linker-payloads carrying PNU.